Mr. Brent Willis reports

VOYAGEUR PHARMACEUTICALS FILES AUDITED ANNUAL FINANCIAL STATEMENTS AND GRANTS STOCK OPTIONS

Voyageur Pharmaceuticals Ltd. has filed its annual audited financial statements and management's discussion and analysis for the year ended Nov. 30, 2023, on SEDAR+.

Option grant

Voyageur also announces that it has granted 3.7 million stock options to directors, officers and consultants of the company pursuant to its incentive stock option plan. On March 26, 2024, the board approved the grant of options, to be effective on March 26, 2024, with an exercise price equal to that of the closing price on that day of seven cents per share. The options were issued with 3.4 million options vesting 12 months from the date of issue and having a five-year term, and the remaining 300,000 options vesting immediately and having a 10-year term. The options are subject to regulatory and TSX Venture Exchange approval.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium, iodine and carbon active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium, iodine and carbon contrast imaging market, Voyageur aims to become a key player by producing its own barium, iodine and fullerene minerals.

We seek Safe Harbor.